Prenetics Global (PRE) to Announce Quarterly Earnings on Tuesday

Prenetics Global (NASDAQ:PRE) is expected to be posting its Q2 2026 results before the market opens on Tuesday, August 18th. Analysts expect the company to post earnings of ($0.48) per share and revenue of $49.85 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Tuesday, August 18, 2026 at 8:30 AM ET.

Prenetics Global (NASDAQ:PRE) last announced its earnings results on Wednesday, June 10th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.07). The firm had revenue of $35.95 million for the quarter, compared to analyst estimates of $36.00 million. Prenetics Global had a negative net margin of 62.45% and a negative return on equity of 20.33%.

Prenetics Global Stock Up 3.0%

Shares of Prenetics Global stock opened at $18.80 on Tuesday. The business has a fifty day simple moving average of $19.29 and a 200-day simple moving average of $18.86. The stock has a market cap of $317.16 million, a PE ratio of -4.10 and a beta of 0.26. Prenetics Global has a 12 month low of $7.18 and a 12 month high of $23.63.

Institutional Trading of Prenetics Global

Hedge funds have recently modified their holdings of the company. Wells Fargo & Company MN bought a new stake in Prenetics Global during the 4th quarter worth approximately $47,000. JPMorgan Chase & Co. bought a new stake in Prenetics Global during the 3rd quarter worth about $65,000. Boothbay Fund Management LLC bought a new stake in shares of Prenetics Global during the fourth quarter worth approximately $241,000. Jump Financial LLC acquired a new stake in Prenetics Global during the 4th quarter worth $268,000. Finally, Hudson Bay Capital Management LP acquired a new stake in shares of Prenetics Global during the fourth quarter worth $296,000. Institutional investors and hedge funds own 25.01% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. Benchmark increased their target price on shares of Prenetics Global from $30.00 to $40.00 and gave the stock a “buy” rating in a research report on Wednesday, July 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Prenetics Global in a research note on Friday, July 17th. Finally, Wall Street Zen downgraded Prenetics Global from a “hold” rating to a “sell” rating in a research note on Saturday, July 25th. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $34.25.

About Prenetics Global

Prenetics Global (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company’s core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.

Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.